Patients were assigned to the following levels of GAS regimens. Nab-paclitaxel was administered intravenously at 125 mg/m2, followed by intravenous gemcitabine at 1000 mg/m2. A daily dose of S1 was de
Sponsors
Uemura Kenichiro, Department of gastrointestinal Surgery, Hiroshima University Hospital
Conditions
Biological borderline resectable pancreatic cancerPancreatic ductal adenocarcinoma
Phase 2
The phase 2 study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel+S-1 for patients with biological borderline resectable pancreatic cancer.
RecruitingJPRN-UMIN000030717
Start: 2019-03-04Target: 50Updated: 2026-06-29
The phase 2 study of neoadjuvant chemotherapy of GAS for biological borderline resectable pancreatic cancer.
RecruitingJPRN-jRCTs061180009
Start: 2019-03-02Target: 50Updated: 2026-06-29